

Clinically Significant Drug Interactions between HIV and CNS drugs

Saye Khoo

HIV Pharmacology Group

University of Liverpool / Biomedical Research Centre in Microbial Diseases

Points for discussion

- HIV Pharmacology for non-specialists
- Two challenging diseases to treat
- Clinically significant drug interactions
 - how common are they ?
 - what is a 'clinically significant' drug interaction ?
 - which antidepressants can I give ?
 - which anti-psychotics can I give ?
 - which anti-convulsants can I give ?
- Strategies for safe prescribing

Swiss Cohort


Patients are getting older

Proportion aged > 50:

•1994 10% •2003 20%


•2006 25%

- .. and take many medications.
- n = 1471 (2008-2009)
- 10-15% lipid lowering, antidepressants, sedatives
- 7-10% acid-reducing, antithrombotic, ACE inhibitors



Co-morbidities increase with age

Medical comorbidities amongst 66,840 HIV- and 33,420 HIV+ veterans



The challenge of treating two diseases

HIV-associated dementia

Depression, anxiety

Psychosis

Seizures

Coping issues

- Denial
- 'self-sabotage'
- Religious beliefs, etc

Lifestyle

- Drug use
- chaotic

Impacts on HIV treatment:

Adherence

Adherence

Drug interactions CNS toxicity of efavirenz

Adherence


Drug interactions Overlapping toxicity

Conflicting treatment priorities Drug interactions

Adherence Treatment refusal


Adherence

Simplicity and Pill Burden




Analysis of 76 studies from a variety of disease areas of electronic monitoring of adherence Compliance was higher: OD vs TID: p = 0.008OD vs QID: p < 0.001BID vs QID: p = 0.001






- Once-daily therapy was considered the best lifestyle fit by 81% of participants
- Total number of pills also important factor with participants reporting that even modest reductions in pill burdens would improve adherence

Adherence-viraemia-resistance relationships






FIRST Trial: Relationship between Adherence and resistance by drug class:

Gardner et al CROI 2008 Abs 777 & AIDS 2010;24:395


Antiretroviral forgiveness 72 h LPV (bd) concentrations






Antiretroviral forgiveness 72 h LPV (qd) concentrations






Antiretroviral forgiveness 72 h ATV (qd) concentrations







The life of pills



Inter-individual variability



Drug Metabolizing Enzymes




- Extended = known polymorphisms that affect activity.
- Polymorphisms present in all (?) enzymes.

Wilson et al. *Nature Genetics* 29:265, 2001.

Pharmacogenetic influences on ATV PK


 $CL=CL_0+\theta_1*PXR_1+\theta_2*PXR_2$




OATP 1B1 MDR1 PXR SNP 521 T>C SNP 3435 C>T SNP 63396 C>T

Green = wild type (36 individuals, 69 samples) Grey = heterozygous (59 individuals, 117 samples) Red = mutant (45 individuals, 98 samples)

Steady-state NVP concentrations predicted at <u>200mg</u> bid (90% prediction interval)



Steady-state NVP concentrations predicted at **400mg od (90% prediction interval)**



Time (h)

0

12

Time (h)

16

20

24

Time (h)

24


Primum non nocere – first, do no harm

- ARVs have great potential for interactions – perhaps the greatest for any disease area
- PIs > NNRTIS >>> NRTIS [1]
- Exacerbated by

polypharmacy – treatment of multiple conditions multiple prescribers – 53% drugs dispensed by community pharmacists not recorded in HIV casenotes [2]

widespread use of 'alternative medicines' – patients on ARVs in Canada (n=628 [3]) and the UK (n=229 [4]) frequently took herbals and supplements (~61%); of these 20% could have compromised HIV management.

- 1 Miller CD, et al. Pharmacotherapy. 2007;27(10):1379-86
- 2 de Maat Ann Pharmacother 2002;36:410-15
- 3 Dhalla et al, Compl Therapies in Clin Practice. 2006 12:242-48.
- 4 Ladenheim et al. HIV Med 2008;9:653



How common are HIV Drug Interactions ?

Antiretroviral Medication Errors among Hospitalized Patients with HIV Infection

Darius A. Rastegar, Amy M. Knight, and Jim S. Monolakis

Johns Hopkins Bayview Medical Center, Baltimore, Maryland

Baltimore [Rastegar, et al, CID 2006;43:933-8]


- 209 admissions of patients receiving ARVs over 1 year
- Contraindicated medications were prescribed in 5.2%

Risk for clinically significant interactions

Study	Year	Setting	N	CSDI	lower	Screening Tool	Adverse	Notes
de Maat et al	2004	Netherlands (hospital)	115 105	26% 23%	N/A	Liverpool website	N/A	Pharmacy screening effective, further pharmacy input not
Shah et al	2007	USA (Medicaid)	571 (689)	30% (15%)	8% (4%)	Liverpool website Micromedex	no VL impact	Audit, and re-audit.
Miller et al	2007	USA (hospital)	153	41%	N/A	DHHS SPC / PI Micromedex	N/A	Age >42y (OR 2.9) >3 conditions (OR 3.0) >3 ARVs (OR 2.4) PI use (OR 11.5)
Kigen et al	2009	Kenya (hospital)	996	34%*	1 2%	Liverpool website	N/A	
Marzolini et al	2009	Switzerland (hospital)	1497	40%	4%	Liverpool website	no CD4 or VL impact	Antiviral Ther 2010
Evans-Jones et al	2009	UK (hospital)	159	27%	15%	Liverpool website	N/A	CID 2010 Only 36% CSDIs correctly identified

* excludes ARV-ARV interactions

Swiss Cohort




68% of 1497 HIV patients were taking co-medications.

• 31% - CNS drugs (anxiolytics – 13%, antidepressants – 12%, anti-psychotics – 3% anticonvulsants – 3%)

4% of interactions could have lowered ARV levels

Marzolini et al AVT 2010 (in press)

How common are HIV Drug Interactions ?



Kenya [Kigen et al. HIV8, 2008 Abstract O121]

- 996 consecutive patients receiving ARVs
- Moderate / Major drug interactions identified in 34%
- 12% (1:3 CSDIs) could have lowered ARV concentrations
- Rifampicin > Azoles > Steroids > Antimalarials > PPIs

HIV Drug Interaction resources

- www.hiv-druginteractions.org
- www.hivinsite.com
- www.tthivclinic.com/interact_tables.html
- www.hopkins-hivguide.org
- www.clinicalcareoptions.com/HIV.aspx
- www.medscape.com/druginfo/druginterchecker

RATING QUALITY OF EVIDENCE AND STRENGTH OF RECOMMENDATIONS

GRADE: an emerging consensus on rating quality of evidence and strength of recommendations

Traffic light summary of Drug-Drug interactions

Liverpool Website Definition:

GRADE Equivalent

Is it safe to administer both drugs ?



- No clinically significant interaction, or interaction unlikely
- Potential interaction that may require close monitoring, alteration of drug dosage or timing of administration

- Interaction likely, do not use or use with caution
- abla No clear data, actual or theoretical

YES

Probably YES if
Benefit outweighs risk, or
Interaction safely managed
Probably NO if
Risk outweighs benefit
Interaction not safely managed

NO

DONT KNOW






Assessing Quality of Evidence

GRA	DE equivalent	Downgrade*	Upgrade*
High	Evidence obtained from at least one properly designed and executed randomized controlled trial.	Study Quality •serious limitations (-1) •very serious limitations (-2) •important inconsistency (-1/-2)	 <u>Strong association</u> strong, no confounders, consistent & direct evidence (+1)** very strong, no major threats to validity, direct evidence (+2)***
Moderate		Directness •some uncertainty (-1) •major uncertainty (-2) sparse or imprecise data (-1) probability of publication bias (-1)	 evidence of dose response gradient (+1) all plausible confounders would have reduced effect (+1)
Low	Evidence obtained from observational studies.		
Very Low			
			ts anisms of drug disposition duct Information / SPC







Interaction Charts	News & Archive	About Us	Pharmacology Res	ources Links	Meetings	TDM a Interacti	Feedback	Home
					Did	g mieraci	on charts	
Printabl	e charts View all V	View all Protease Inf	nibitors View all NNRTIs	I View all NRTIS View	w all Entry/Integrase I	nhibitors B	lack to start	
Step 1 Choose one	or more HIV drugs							Next >>
Step 2 Choose one	or more combination o	classes						
Step 3 Choose one	or more combination o	drugs					_	
Step 4 View results								
otease Inhibitors	NN	IRTIs	NR	Tis	En	try & Integra	se Inhibitors	
Atazanavir		Delavirdine		Abacavir	N	Maraviroc		
Darunavir		Efavirenz		Didanosine (ddl)	V	Raltegravir		
Fosamprenavir		Etravirine	V.	Emtricitabine (FTC)				
Indinavir		Nevirapine	V	Lamivudine (3TC)				
Lopinavir			—	Stavudine (d4T)				
Nelfinavir				Tenofovir				
Ritonavir			V.	Zidovudine (AZT/ZDV)				
Saquinavir								
Tipranavir								

- n			www.hiv-	0		a series and the	0	
teraction Charts	News & Archive	About Us	Pharmacology Resources	Links	Meetings	TDM	Feedback	Home
					D	rug Intera	ction Charts	
Printabl	e charts View all Vie	w all Protease Inhi	ibitors View all NNRTIs View a	all NRTIs Viev	v all Entry/Integras	e Inhibitors	Back to start	
								Next >
			Search by alphabetical list of	f drugs				
			C Search by drug class					
								Next >

on Charts	News & Archive	About Us	Pharmacology Resources	Links	Meetings	TDM	Feedback	Home		
Drug Interaction C										
Printable ch	arts View all View	w all Protease Inh	nibitors View all NNRTIs View al	INRTIS Viev	/v all Entry/Integrase	Inhibitors	Back to start			
				(FTC), Etravirin	ie, Lamivudine (3T)	 Lopinavir 	r, Ar	mend selection		
Choose one or m	ore combination clas	ses						Next >>		
Choose one or m	ore combination drug	gs								
View results										
	Printable ch Searching by: Aba Maraviroc, Nevira Choose one or m Choose one or m	Printable charts View all View Searching by: Abacavir, Atazanavir, Da Maraviroc, Nevirapine, Raltegravir, Rit Choose one or more combination clas Choose one or more combination drug	Printable charts View all View all Protease Inf Searching by: Abacavir, Atazanavir, Darunavir, Didano Maraviroc, Nevirapine, Raltegravir, Ritonavir, Tenofovi Choose one or more combination classes Choose one or more combination drugs	Printable charts View all View all Protease Inhibitors View all NNRTIs View al Searching by: Abacavir, Atazanavir, Darunavir, Didanosine (ddl), Efavirenz, Emtricitabine (Maraviroc, Nevirapine, Raltegravir, Ritonavir, Tenofovir, Zidovudine (AZT/ZDV) Choose one or more combination classes Choose one or more combination drugs	Printable charts View all View all Protease Inhibitors View all NNRTIs View all NRTIs View Searching by: Abacavir, Atazanavir, Darunavir, Didanosine (ddl), Efavirenz, Emtricitabine (FTC), Etravirin Maraviroc, Nevirapine, Raltegravir, Ritonavir, Tenofovir, Zidovudine (AZT/ZDV) Choose one or more combination classes Choose one or more combination drugs	Printable charts View all View all Protease Inhibitors View all NNRTIs View all NRTIs View all Entry/Integrase Searching by: Abacavir, Atazanavir, Darunavir, Didanosine (ddl), Efavirenz, Emtricitabine (FTC), Etravirine, Lamivudine (3TC Maraviroc, Nevirapine, Raltegravir, Ritonavir, Tenofovir, Zidovudine (AZT/ZDV) Choose one or more combination classes Choose one or more combination drugs	Drug Interact Printable charts View all View all Protease Inhibitors View all NNRTIs View all NRTIs View all Entry/Integrase Inhibitors Searching by: Abacavir, Atazanavir, Darunavir, Didanosine (ddl), Efavirenz, Emtricitabine (FTC), Etravirine, Lamivudine (3TC), Lopinavir Maraviroc, Nevirapine, Raltegravir, Ritonavir, Tenofovir, Zidovudine (AZT/ZDV) Choose one or more combination classes Choose one or more combination drugs	Drug Interaction Charts Printable charts View all View all Protease Inhibitors View all NNRTIS View all NRTIS View all Entry/Integrase Inhibitors Back to start Searching by: Abacavir, Atazanavir, Darunavir, Didanosine (ddl), Efavirenz, Emtricitabine (FTC), Etravirine, Lamivudine (3TC), Lopinavir, Maraviroc, Nevirapine, Raltegravir, Ritonavir, Tenofovir, Zidovudine (AZT/ZDV) Choose one or more combination classes Choose one or more combination drugs		

Click here to select from an alphabetic list of drugs instead of by class.

Classes		
Analgesics	Antiarrhythmics	Antibacterials
Anticonvulsants	Antidepressants	Anti-diabetics
Antifungals	Antihistamines	Antimigraine Agents
Antineoplastics	Anti-platelet and Anti-coagulant	Antiprotozoals
Antipsychotics/Neuroleptics	Antiretrovirals (Entry Inhibitors)	Antiretrovirals (Integrase Inhibitors)
Antiretrovirals (Maturation Inhibitors)	Antiretrovirals (NNRTIS)	 Antiretrovirals (Nucleoside/tide Analogues)
Antiretrovirals (Nucleotide Analogues)	Antiretrovirals (Protease Inhibitors)	Antivirals
Anxiolytics/Hypnotics/ Sedatives	E Beta Blockers	Bronchodilator
Calcium Channel Antagonists	Erectile Dysfunctional Agents	Gastrointestinal Agents
Gastrointestinal Agents	General Anaesthetics	Heart Failure Agents

	Interact	tion Charts	News & Archive	About Us	Pharmacology Resources	Links	Meetings	TDM	Feedback	K Home
							Dr	ug Interac	tion Charl	s
		D. Jakabila			The second state of the se			1-1-1-11-11	D 1 - 1 1 1	
		Printable	charts view all viev	v all Protease inn	ibitors View all NNRTIs View a	INKIIS VIEW	ali Entry/integrase	Innibitors	васк to start	
	Step 1		bacavir, Atazanavir, Da tegravir, Ritonavir, Teno		ne (ddl), Efavirenz, Emtricitabine (l (AZT/ZDV)	TC), Etravirine,	Lamivudine (3TC), Lopinavir, I	Maraviroc,	Amend selection
	Step 2	Searching by: A	ntipsychotics/Neurolep	tics						Amend selection
	Step 3	Choose one or	more combination drug	s						Next >>
	Step 4	View results								
An	tineveho	tice/Nouroloptics		Antiretro	wirale		Antiretrovirals			
	Chlorpr	tics/Neuroleptics			hibitors)		(Integrase Inhib	itors)		
	Clozapi			🗖 Enfu	virtide (T20)		Elvitegravir			
				🔽 Mara	wiroc		Raltegravir			
	Olanzap									
	Pimozid			_						
_	Risperio									
	Thiorida									
Δ IP	tiretrovir			Antiretro	wirale		Antiretrovirals			
	NRTIS)	<u></u>			side/tide Analogues)		(Protease Inhibi	tors)		
	Delavird	line		🔽 Abao			Matazanavir			
न				_			_			

Key to symbols:

Clicking on a solid symbol within a table will give further information on the interaction. Empty symbols indicate that the combination has not been studied and an interaction has been predicted based on the metabolic profiles of the drugs.

●/●	These drugs should not be coadministered
∎,∎	Potential interaction - may require close monitoring, alteration of drug dosage or timing of administration
♦/♦	No clinically significant interaction expected
* / \$	There are no clear data, actual or theoretical, to indicate whether an interaction will occur
n/a	Data not available

PDF

We version a series with the series a series with the series of the series and the series with the series of the series and th

Antipsychotics/Neuroleptics	Atazanavir	Darunavir	Lopinavir	Ritonavir	Efavirenz	Etravirine	Nevirapine
Clozapine					♦	♦	♦
Haloperidol							
Olanzapine							
Pimozide	0	0	Θ	0	0		
Quetiapine							
Risperidone	♦		♦		♦	♦	♦
Sulpiride	♦	♦	♦	♦	♦	♦	♦
Antiretrovirals	Atazanavir	Darunavir	Loninavir	Ritonavir	Efavironz	Etravirine	Neviranine
 ▲ 							•



Interaction Report from www.hiv-druginteractions.org

Report ID: PYSCH

Date Produced: 05 May 2010

Antiretroviral treatment	Co-medications	
Darunavir	Clozapine	
Etravirine	Haloperidol	
Raltegravir	Olanzapine	
Ritonavir	Pimozide	
	Quetiapine	
	Risperidone	
	Sulpiride	

This report lists the potentially clinically significant interactions (i.e. "red" and "amber" classifications) for the drugs in the table above. Interactions with a "green" classification (i.e. no clinically significant interaction expected) have been checked but are not shown on this report.

For full details of all interactions, see www.hiv-druginteractions.org.

Description of the interactions

Drugs that should not be co-administered (RED)

- Darunavir and Pimozide: Coadministration is contraindicated as it may increase pimozide concentrations which may result in serious and/or life threatening reactions such as cardiac arrhythmias.
- Ritonavir and Pimozide: Coadministration is contraindicated as it is likely to increase pimozide concentrations and the potential for serious and/or life threatening
 reactions such as cardiac arrhythmias.

Potential interaction – may require close monitoring, alteration of drug dosage or timing of administration (AMBER)

- Darunavir and Clozapine: This interaction has not been studied. An interaction has been predicted based on the metabolic profiles of the drugs.
- Darunavir and Haloperidol: This interaction has not been studied. An interaction has been predicted based on the metabolic profiles of the drugs.
- Darunavir and Olanzapine: This interaction has not been studied. An interaction has been predicted based on the metabolic profiles of the drugs.
- Darunavir and Quetiapine: This interaction has not been studied. An interaction has been predicted based on the metabolic profiles of the drugs.

$(\mathbf{ } \mathbf{ })$

Drug Interactions – Anti-psychotics

	-	EMEA:	hema	atolog	gical t	oxicity	y												
				\bigwedge															
	ΑΤΥ	DRV	FPV	LPV	RTV	sqv	TPV	EFV	ETR	NVP	ABC	ddI	FTC	ЗТС	d4T	TDF	ZDV	MVC	RAL
Chlorpromazine			-					\$	\$	٠	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Clozapine								\$	\$	٠	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Haloperidol	•		۰	۰					۰		n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Olanzapine	•										n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Pimozide	•	•	•	•	•	•	•	•			n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Quetiapine											\$	٠	٠	٥	٥	٠	٠	n/a	n/a
Risperidone	٠		٠	٠		\$	٠	\$	٠	٠	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Sulpiride	٠	٠	\$		٠	٠	\$	٠		\$	٠	٠	٠	٥	٥			n/a	n/a

(\mathbf{D})

Drug Interactions – Anti-psychotics

	ATV	DRV	FPV	LPV	RTV	sqv	TPV	EFV	ETR	NVP	ABC	ddI	FTC	зтс	d4T	TDF	ZDV	MVC	RAL
Chlorpromazine								\$	٠	٠	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Clozapine								\$	٠	٠	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Haloperidol											n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Olanzapine					\bigcirc						n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Pimozide	0	0	•	•	•	•	•				n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Quetiapine										R	\$	٠	٠	٠	٠	٠	٠	n/a	n/a
Risperidone	\$		\$	٠		ł	٠	٠	٠	\$	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Sulpiride	٠	٠	٥	٥	٠	۵	٠	٠	٠	٠	٥	\$	¢	۵	٠	٠	٠	n/a	n/a
			Olanzipine AUC ↓ 50%											1	halo	perid	lol.		
2 case reports	↑	risper	idone	•															

()

Drug Interactions – Anti-psychotics

	ATV	DRV	FPV	LPV	RTV	sqv	TPV	EFV	ETR	NVP	ABC	ddI	FTC	зтс	d4T	TDF	ZDV	MVC	RAL
Chlorpromazine								٠	٠	٠	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Clozapine		•				۰		٠	٠	٠	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Haloperidol		•				۰					n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Olanzapine											n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Pimozide	⊜	⊜	⊜	•	⊜	⊜	Θ	Θ			n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Quetiapine					۰	۰			•		\$	\$	٠	\$	\$	\$	\$	n/a	n/a
Risperidone	٠		٠	۰		٠	٠	٠	٠	٠	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Sulpiride	٠	٠	•	٠	٠	٠	٠	٠	٠	٠	\$	٠	٠	٠	\$	٥	٠	n/a	n/a

↑ risk arrhythmia

Drug Interactions – Anti-depressants

	ATV	DRV	FPV	LPV	RTV	SQV	TPV	EFV	ETR	NVP	ABC	ddI	FTC	ЗТС	D4T	TDF	ZDV	MVC	RAL
Amitriptyline								٠	٠	٥	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Citalopram											n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Clomipramine								•			\$	\$	\$	\$	٠	٠	٠	٠	\$
Desipramine								٠	٠	٠	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Doxepin								٠	٠	٠	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Fluoxetine								٠	٠	٠	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Lithium		\$	\$		\$	\$	٠	٠	٠	٠	٠	٠	٠	\$	٠	٠	٠	٠	\$
Mirtazapine											n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Nortriptyline								٠	٠	٠	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Paroxetine								٠		٠	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Sertraline						•					n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Venlafaxine											\$	\$	٠	٠	٠	٠	٠		\$

Which Anticonvulsant ?

Anticonvulsants	ATV	DRV	FPV	LPV	RTV	SQV	TPV	EFV	ETR	NVP
Carbamazepine	-								8	
Clonazepam		F						•		
Ethosuximide		F	R	r		•				
Gabapentin	۲	\odot	9	۲	۲	۲	۲	٥	\odot	۲
Lamotrigine		۲	0			۲	۲	۲	۲	٢
Levetiracetam	۲	۲	•	۲	۲	۲	۲	۲	۲	۲
Oxcarbazepine		•	п	•		•		٥		п
Phenobarbital		8							8	п
Phenytoin		8							8	
Valproate	•	Ø	Ø			۲		\diamond	۲	
Vigabatrin	\odot	۲	6	۲	۲	ø	۲	0	\odot	Ø

What can be done?

- In HIV therapy, DDIs are largely unavoidable... but the majority are manageble
- Physician awareness and recognition is poor

unrecognised drug interactions are amongst the commonest causes of serious medication error

• Unexpected interactions still catch us out e.g. SQVr and PPIs, TDF and ddl, LPVr and rosuvastatin No substitute for doing interaction studies

the problem will not go away with new drugs

longer survival – polypharmacy decentralised care – to general practitioners (developed countries), or to districts (developing countries)

 still 'black holes' in our knowledge contraceptives – oral > injectables > patches herbals, etc

Interventions which work

- Prescriber education
- Pharmacist input [1-2]

Drug interactions databases

<u>www.hiv-druginteractions.org</u>, <u>www.clinicalcareoptions.com</u>, etc Concordance is variable [3] Tendency to over-call – 'Alert fatigue' !

'Active vs passive' identification of interactions

Decision support software for dispensaries / electronic prescribers Interaction datasheets for patients or prescribers

- 1 Hanlon Am J Med 1996;100;428.
- 2 de Maat J Clin Pharm Ther 2004;29:121
- 3 Pham. CPT 2008;83:396

Interventions which work

- Stick to a few known drugs
- Keep it simple Once- or twice- daily dosing
 given once or twice a day
- Therapeutic Drug Monitoring

to manage interactions, or else to discount them

1 Hanlon Am J Med 1996;100;428.

- 2 de Maat J Clin Pharm Ther 2004;29:121
- 3 Pham. CPT 2008;83:396

Resource-limited settings

- Training to improve quality of prescribing
- Drug Information Centres e.g. ATIC
- Programmatic approach e.g. national protocols for treatment of TB-HIV co-infection, use of fluconazole prophylaxis
- Instituting systems for pharmacovigilance
- Incorporate monitoring for serious DDIs within ARV Programmes

Acknowledgements

David Back Sara Gibbons Andrew Owen Laura Dickinson Laura Else Neill Liptrott Helen Reynolds Wai San Kwan Gabriel Kigen Kay Seden

Marta Boffito Wolfgang Stoehr David Dunn John Tjia Maxine Dunham Marco Siccardi Gianni diPerri Stefano Bonora Ceppie Merry

... and many others....

Declaration of Interests

www.hiv-druginteractions.org

Receives sponsorship from GSK, Abbott, Merck, BMS, Tibotec, Roche, Gilead, Pfizer. Editorial content remains independent.

Therapeutic Drug Monitoring

TDM in the UK is sponsored by Roche, Abbott, Merck, GSK, Roche. The University has spun TDM services into Delphic (SK serves as non-exec director)